Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study

Approximately 3.5 million children and adolescents worldwide are chronically infected with HCV. This study uses pharmacokinetic modeling to identify pediatric doses of elbasvir/grazoprevir (EBR/GZR) that achieve plasma concentrations similar to those seen in adults receiving the approved fixed-dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Peralta, Regino P., Wirth, Stefan, Squires, Robert H., Mutschler, Frauke, Lang, Thomas, Pawlowska, Malgorzata, Sluzewski, Wojciech, Majda-Stanislawska, Ewa, Fischler, Bjorn, Balistreri, William F., Jonas, Maureen M., Blondet, Niviann, Rosenthal, Philip, Alkhouri, Naim, Romero, Rene, Grandhi, Anjana, Castronuovo, Patricia, Caro, Luzelena, Du, Lihong, Rosenbloom, Daniel I.S., Haber, Barbara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931032/
https://www.ncbi.nlm.nih.gov/pubmed/36790337
http://dx.doi.org/10.1097/HC9.0000000000000031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931032/
https://www.ncbi.nlm.nih.gov/pubmed/36790337
http://dx.doi.org/10.1097/HC9.0000000000000031

Ejemplares similares